CRISPR Therapeutics advances one-time cardiovascular strategy as CTX310 lipid reductions persist for a year

CRISPR Therapeutics has strengthened the case for expanding gene editing into cardiovascular medicine after one-year CTX310 data showed that substantial reductions in cholesterol and triglycerides persisted following a single intravenous treatment. The durability result is strategically important because the company is attempting to move CRISPR beyond rare genetic diseases and into much larger cardiometabolic markets where conventional therapies typically require years or decades of repeated dosing. At the highest tested dose, CTX310 reduced ANGPTL3 by an average 79%, triglycerides by 48% and low-density lipoprotein cholesterol by 53% after one year. CRISPR Therapeutics is already testing a fixed-dose regimen in Phase 1b and expects additional data from patients with severe hypertriglyceridemia later in 2026. Despite the encouraging clinical update, CRISPR Therapeutics shares fell about 3% in afternoon trading as investors weighed the early-stage nature of the program against its potentially large long-term opportunity.

The findings were presented in a late-breaking session at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine. All 15 participants enrolled in the Phase 1a dose-escalation portion had reached at least one year of follow-up, allowing CRISPR Therapeutics to address one of the most important questions surrounding a permanent gene-editing treatment: whether its biological effect remains durable after the initial response.

Durable CTX310 results strengthen the business case for one-time cardiovascular gene editing

CTX310 is designed to permanently disrupt ANGPTL3 within liver cells using in vivo CRISPR/Cas9 editing. ANGPTL3 plays an important role in lipid metabolism, and people with naturally occurring loss-of-function variants in the gene tend to have lower levels of LDL cholesterol and triglycerides. CRISPR Therapeutics is attempting to replicate that favorable biology through a single therapeutic intervention rather than continuous pharmacological suppression.

The Phase 1a study enrolled patients whose lipid levels remained inadequately controlled despite existing treatment. Participants included people with homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, severe hypertriglyceridemia and mixed dyslipidemia. Most were already receiving statins or ezetimibe, while 40% were taking PCSK9 inhibitors, positioning CTX310 initially toward patients with substantial residual treatment needs rather than the broad population using routine cholesterol medication.

Dose-dependent effects remained visible through one year. At the highest 0.8 milligram-per-kilogram dose, mean circulating ANGPTL3 declined 79%, with a maximum reduction of 89%. Mean triglycerides fell 48%, with a maximum reduction of 78%, while mean LDL cholesterol declined 53%, with one participant reaching an 84% reduction.

For CRISPR Therapeutics, persistence of those effects may be as important as their initial magnitude. Established lipid-lowering drugs can produce large cardiovascular benefits, but effectiveness depends on patients continuing treatment. A successful one-time therapy would shift the commercial proposition from chronic medication toward an intervention intended to provide long-lasting biological modification after a single course.

That model could be particularly attractive in inherited lipid disorders and severe hypertriglyceridemia, where patients may require combinations of medicines and still fail to reach treatment targets. It also gives CRISPR Therapeutics a route into cardiovascular medicine without initially competing for the entire mass-market cholesterol population.

The opportunity remains early. Fifteen patients are far too few to establish the consistency of efficacy required for a commercial cardiovascular product, while reductions in LDL cholesterol and triglycerides do not themselves demonstrate fewer heart attacks, strokes or cardiovascular deaths. Larger studies will have to establish whether permanent ANGPTL3 editing produces a sufficiently favorable benefit-risk profile to justify an irreversible intervention.

CTX310 could establish a platform extending well beyond a single cholesterol program

The larger investment implication is that CTX310 is not an isolated cardiovascular experiment. CRISPR Therapeutics has built a proprietary lipid nanoparticle delivery platform designed to carry gene-editing machinery into the liver, and the company is using that infrastructure across several cardiovascular programs.

CTX340 targets angiotensinogen and is being developed for refractory hypertension, while CTX321 targets LPA for patients with elevated lipoprotein(a). CRISPR Therapeutics also has CTX460 targeting SERPINA1 in alpha-1 antitrypsin deficiency, demonstrating how the same liver-editing capabilities could support candidates across cardiovascular and rare diseases.

That gives the CTX310 data significance beyond its immediate indication. Successful clinical validation would support not only ANGPTL3 editing but also CRISPR Therapeutics’ ability to repeatedly deliver gene-editing components directly into patients and achieve predictable biological effects in liver cells.

This represents an important evolution from CASGEVY, the company’s first approved CRISPR-based therapy developed with Vertex Pharmaceuticals. CASGEVY uses an ex vivo model in which a patient’s stem cells are collected, edited outside the body and returned after conditioning treatment. CTX310 instead introduces gene-editing machinery directly into the patient, a potentially more scalable model if safety, manufacturing and efficacy can be established across broader populations.

CRISPR Therapeutics already has growing commercial exposure through CASGEVY. The therapy generated $76 million in second-quarter 2026 revenue, representing growth of 78% from the previous quarter and 151% year over year. Under the collaboration, Vertex Pharmaceuticals leads global commercialization while the companies share program economics on a 60/40 basis.

The company also ended June with $2.36 billion in cash, cash equivalents and marketable securities, compared with approximately $1.98 billion at the end of 2025. That balance sheet provides substantial capacity to finance the cardiovascular pipeline through additional clinical development while continuing investment across autoimmune disease, oncology, regenerative medicine and rare diseases.

Phase 1b safety and efficacy data will determine how quickly CTX310 can move toward larger trials

The one-year safety update was broadly reassuring. CRISPR Therapeutics reported no treatment-related serious adverse events, no dose-limiting toxicities and no Grade 3 or higher liver transaminase changes during Phase 1a. No additional treatment-related adverse events emerged during extended follow-up.

Previously reported events included one allergic reaction that resolved with supportive care and three Grade 2 infusion-related reactions. One participant with elevated liver enzymes before treatment experienced a temporary increase after dosing, but levels subsequently returned to baseline.

Long-term surveillance will be especially important because CTX310 is designed to make a permanent genetic change. Regulators evaluating a therapy for cardiovascular disease are likely to require confidence that unintended editing, liver toxicity or other delayed complications remain acceptably low, particularly if development eventually expands beyond patients with severe refractory disease.

CRISPR Therapeutics has moved the program into Phase 1b using a fixed flat dose corresponding to the most effective exposure tested in Phase 1a. The next update is expected to focus on patients with severe hypertriglyceridemia, which should give investors a better view of efficacy and tolerability in a more clearly defined treatment population.

That could begin defining the first realistic commercial pathway for CTX310. Targeting severe disease with substantial residual risk may provide a more achievable route to regulatory development than immediately pursuing millions of patients with ordinary hypercholesterolemia who already have multiple effective treatment choices.

CRISPR Therapeutics stock slips as investors look for larger CTX310 datasets

CRISPR Therapeutics shares were trading around $57.53 at 1:42 p.m. Eastern on August 28, down approximately 3.1% from the previous close of $59.37. The shares had gained 6.7% on August 25, suggesting that investors had already positioned ahead of the European Society of Cardiology presentation.

The restrained response is consistent with CTX310’s current development stage. The durability findings strengthen the biological rationale, but a 15-patient Phase 1a study is unlikely to meaningfully resolve questions surrounding commercial potential, long-term safety or regulatory requirements.

Analyst sentiment also reflects that balance between opportunity and uncertainty. Citizens recently reiterated a Market Outperform rating and an $80 price target ahead of the CTX310 presentation, while Morgan Stanley has described the durability findings as encouraging. Other firms remain more cautious, with Goldman Sachs maintaining a Neutral rating despite recently increasing its price target to $55.

CRISPR Therapeutics also remains loss-making despite its substantial cash position. The company reported a second-quarter net loss of $91.2 million, improved from a $208.5 million loss a year earlier, while research and development expenses totaled $67.2 million. Its financial resources reduce near-term funding pressure, but the breadth of its pipeline means capital allocation will remain important as multiple programs move into increasingly expensive clinical stages.

The investment case for CTX310 therefore hinges less on Friday’s share-price reaction and more on whether subsequent trials reproduce the magnitude and durability of lipid reductions in larger populations. If the platform continues to perform consistently, CRISPR Therapeutics could establish a cardiovascular franchise that materially expands the addressable market for gene editing beyond the rare-disease settings where the technology first reached patients.

Key takeaways from CTX310’s one-year results and CRISPR Therapeutics’ cardiovascular strategy

• A single CTX310 treatment maintained substantial ANGPTL3, triglyceride and LDL cholesterol reductions through one year.
• At the highest dose, mean ANGPTL3 fell 79%, triglycerides declined 48% and LDL cholesterol dropped 53%.
• The durability supports CRISPR Therapeutics’ strategy of developing one-time treatments that could reduce dependence on lifelong cardiovascular medication.
• Phase 1a enrolled only 15 patients, leaving larger studies necessary to establish efficacy consistency and long-term safety.
• CTX310 has moved into Phase 1b, with additional severe hypertriglyceridemia data expected later in 2026.
• CRISPR Therapeutics is using the same liver-editing platform across CTX340 for refractory hypertension and CTX321 for elevated lipoprotein(a).
• CASGEVY generated $76 million in second-quarter revenue, giving CRISPR Therapeutics growing commercial exposure alongside its expanding pipeline.
• CRISPR Therapeutics held approximately $2.36 billion in cash and investments at June 30, providing substantial resources for clinical development.
• CRISPR Therapeutics shares fell about 3% after the CTX310 presentation despite encouraging durability data.
• Future valuation will depend increasingly on whether larger CTX310 studies confirm safety, durability and a clear regulatory pathway for cardiovascular gene editing.